# US 2022/0017608 A1 · Methods of Treating Inflammatory Pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0017608 A1
- Document ID: US20220017608A1
- Status: Published application
- Kind: A1
- Application number: 17/184,220
- Filed: 2021-02-24
- Published: 2022-01-20
- Earliest claimed: 2008-03-04
- Assignees: Teva Pharmaceuticals International GmbH
- Applicants: Teva Pharmaceuticals International GmbH
- Inventors: Kristian Todd Poulsen; David Louis Shelton; Joerg Zeller; Ian Machin; Laura Corradini
- Web page: https://patentgrep.com/patent/US20220017608A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/24: Antidepressants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of inflammatory pain and/or symptoms of inflammatory pain, and to a method of treating and/or preventing inflammatory pain and/or symptoms of inflammatory pain using an anti-CGRP antibody.

## Claims

### Claim 1

A method for preventing and/or treating inflammatory pain and/or symptoms of inflammatory pain, comprising peripheral administration to the individual of an effective amount of an anti-CGRP antagonist antibody.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the medicament is prepared to be peripherally administered.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the medicament is administered peripherally.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the medicament is prepared to be administered orally, sublingually, via inhalation, transdermally, subcutaneously, intravenously, intra-arterially, intra-articularly, peri-articularly, locally and/or intramuscularly.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the medicament is prepared to be administered subcutaneously or intravenously.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antagonist antibody acts peripherally on administration.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the inflammatory pain is arthritic pain.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the arthritic pain is osteoarthritis pain.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antagonist antibody:
(a) binds to CGRP;
(b) blocks CGRP from binding to its receptor;
(c) blocks or decreases CGRP receptor activation;
(d) inhibits blocks, suppresses or reduces CGRP biological activity;
(e) increases clearance of CGRP; and/or
(g) inhibits CGRP synthesis, production or release.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antagonist antibody:
(i) is a human antibody,
(ii) is a humanized antibody,
(iii) is a monoclonal antibody,
(iv) binds CGRP with a Kd of 50 nM or less (as measured by surface plasmon resonance at 37° C.); and/or
(v) has a half life in-vivo of at least 7 days.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antagonist antibody specifically binds to the C-terminal region of CGRP.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the anti-CGRP antagonist antibody specifically recognises the epitope defined by the sequence GSKAF.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antibody comprises a VH domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 1 or 19.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antibody comprises a VL domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 2 or 20.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the anti-CGRP antibody further comprises a VH domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 1 or 19.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antibody comprises at least one CDR selected from the group consisting of:
(a) CDR H1 as set forth in SEQ ID NO: 3 or 21;
(b) CDR H2 as set forth in SEQ ID NO: 4 or 22;
(c) CDR H3 as set forth in SEQ ID NO: 5 or 23;
(d) CDR L1 as set forth in SEQ ID NO: 6 or 24;
(e) CDR L2 as set forth in SEQ ID NO: 7 or 25;
(f) CDR L3 as set forth in SEQ ID NO: 8 or 26; and
(g) variants of L1, L2 and H2.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antibody comprises a VH domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 1 and a VL domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 2.

### Claim 18 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antibody comprises a heavy chain produced by the expression vector with ATCC Accession No. PTA-6867.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antibody comprises a light chain produced by the expression vector with ATCC Accession No. PTA-6866.

### Claim 20 (depends on 1)

The method according to claim 1, wherein the anti-CGRP antibody is produced by the expression vectors with ATCC Accession Nos. PTA-6867 and PTA-6866.

### Claim at position 21

-31. (canceled)
